The higher RTG seen in patients with T2DM seems to result from increased renal SGLT2 expression; therefore, inhibition of SGLT2 represents an efficacious glucose-lowering therapeutic strategy [22]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.